What Can We Learn From Novartis AG ADR (NVS)’s Valuation Ratios?

Novartis AG ADR (NYSE:NVS) traded with an addition of $1.84 to $102.10 on Thursday, an upside of 1.84 percent. An average of 1,053,896 shares of common stock have been traded in the last five days. There was a gain of $0.12 in the past week, and it reached a new high 35 times over the past 12 months. The last 20 days have seen an average of 1,078,949 shares traded, while the 50-day average volume stands at 1,039,530.

NVS stock has decreased by -1.14% in the last month. The company shares reached their 1-month lowest point of $96.91 on 09/06/23. With the stock rallying to its 52-week high on 07/21/23, shares of the company touched a low of $74.24 and a high of $105.61 in 52 weeks. It has reached a new high 17 times so far this year and achieved 12.55% or $11.49 in price. In spite of this, the price is down -3.32% from the 52-week high.

Valuation Metrics

Novartis AG ADR (NVS) has a trailing price-to-earnings (P/E) ratio of 28.44, which compares with the N/A for the broader industry. The stock’s beta is 0.54. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.08, the price-to-book (PB) ratio at 4.07, and the price-to-cash flow ratio at 14.93.

The company has a payout ratio of 71.32%. The company’s most recent quarterly dividend payment was $3.4694 a share, representing a up of 195.27% from $1.1750 last year. Its latest increase dividend $2.2944 reported on Thursday February 2 2023.

Financial Health

The quick ratio of Novartis AG ADR for the three months ended June 29 was 0.79, and the current ratio was 1.05, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.38 and a total debt to equity ratio of 0.55 for the quarter ending June 29. Its gross profit as reported stood at $36.34 billion compared to revenue of $51.83 billion.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $6.96 billion in the quarter, while revenues were shrunk -245.38%. The analyst consensus anticipated Novartis AG ADR’s latest quarter earnings to come in at $1.68 per share, but it turned out to be $1.83, a 8.90% surprise. For the quarter, EBITDA amounted to $4.77 billion.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Novartis AG ADR (NVS) price momentum. RSI 9-day as of the close on 27 September was 54.64%, suggesting the stock is Neutral, with historical volatility in this time frame at 16.68%.

As of today, NVS’s price is $101.37 +0.11% or $0.12 from its 5-day moving average. NVS is currently trading +0.29% higher than its 20-day SMA and -2.40% lower than its 100-day SMA. However, the stock’s current price level is -0.98% below the SMA50 and +12.37% above the SMA200.

The stochastic %K and %D were 50.77% and 53.75%, respectively, and the average true range (ATR) was 1.37. With the 14-day stochastic at 64.23% and the average true range at 1.33, the RSI (14) stands at 53.05%. The stock has reached -0.65 on the 9-day MACD Oscillator while the 14-day reading was at -0.32.

Analyst Ratings

Morgan Stanley upgraded Novartis AG ADR (NYSE: NVS) to a an Equal-weight rating in its most recent analyst report. Previously, the stock was rated as an Underweight.

Most Popular

Related Posts